The Case for an Unblinded Modeler in Early Clinical Development

Area of Science:

• Clinical Pharmacology
• Quantitative Pharmacology
• Drug Development

Background:

• Early clinical studies are increasingly complex, demanding numerous real-time decisions.
• Modeling and simulation are established for overall drug development but underutilized in high-uncertainty first-in-human (FIH) studies.

Purpose of the Study:

• To discuss the guidance of complex early clinical studies using modeling and simulation.
• To explore methods for unblinding modeling scientists without compromising clinical team blinding.
• To highlight the benefits of quantitative model backbones in early drug development.

Main Methods:

• Utilizing modeling and simulation for real-time study guidance.
• Implementing strategies to prevent unblinding of the clinical team.
• Applying a quantitative model backbone throughout early clinical development.
• Analyzing case studies demonstrating the impact of unblinded modeling.

Main Results:

• Modeling and simulation can efficiently guide complex early clinical studies, including FIH trials.
• Unblinded modeling scientists can leverage emerging data for informed decision-making.
• Case studies show successful dose escalation and study extension supported by modeling and simulation.
• Quantitative modeling enhances subject safety and streamlines drug development.

Conclusions:

• Modeling and simulation are crucial for efficient and safe guidance of early clinical pharmacology studies.
• Maintaining blinding integrity while utilizing unblinded modeling is achievable.
• The application of quantitative models in FIH studies improves the drug development process.